Skip to main content

Table 1 Baseline clinical characteristics and demographics

From: Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial

  Traditional dosing (n = 163) Genotype-guided dosing (n = 159)
Age, mean (SD), years 59.4 (14.5) 58.4 (14.3)
Male, No. (%) 88 (54.0) 100 (62.9)
Weight, mean (SD), kg 66.9 (16.8) 67.3 (14.1)
Race, No. (%)
 Chinese 98 (60.1) 99 (62.3)
 Malay 39 (23.9) 32 (20.1)
 Indian 17 (10.4) 14 (8.8)
 Others 9 (5.5) 14 (8.8)
CYP2C9 genotype, No./total (%)
 Presence of *3 allele 11/160 (6.9) 7/158 (4.4)
VKORC1–381 genotype, No./total (%)
 C/C 91/162 (56.2) 97/159 (61.0)
 C/T 47/162 (29.0) 43/159 (27.0)
 T/T 24/162 (14.8) 19/159 (12.0)
Indication, No./total (%)
 Atrial fibrillation 55/160 (34.4) 61/156 (39.1)
 Stroke 11/160 (6.9) 11/156 (7.1)
 Deep vein thrombosis 44/160 (27.5) 42/156 (26.9)
 Pulmonary embolism 19/160 (11.9) 17/156 (10.9)
 Left ventricular thrombus 17/160 (10.6) 18/156 (11.5)
 Others 26/160 (16.3) 14/156 (9.0)
Amiodarone, No./total (%) 3/159 (1.9) 7/156 (4.5)
Low-molecular weight heparins, No./total (%) 78/159 (49.1) 88/157 (56.1)
Medical history, No./total (%)
 Stroke 16/160 (10.0) 10/157 (6.4)
 Deep vein thrombosis 7/160 (4.4) 4/157 (2.6)
 Pulmonary embolism 2/160 (1.3) 3/157 (1.9)
 Myocardial infarction 8/160 (5.0) 17/157 (10.8)
 Congestive heart failure 21/160 (13.1) 18/157 (11.5)
 Hypertension 86/160 (53.8) 92/157 (58.6)
 Type 2 diabetes mellitus 58/160 (36.3) 56/157 (35.7)
Centre, No. (%)
 National University Hospital, Singapore 144 (88.3) 144 (90.6)
 University of Malaya Medical Centre, Malaysia 15 (9.2) 15 (9.4)
 Tan Tock Seng Hospital, Singapore 4 (2.5) 0 (0.0)